Editorial label review
Alloy side effects: low libido
Primary formulary: Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms
Quick answer
Low libido shows up on the FDA labels for the active ingredients Alloy prescribes — Estradiol (oral and patch) + oral micronized progesterone. This page walks through the labelled frequency ranges, what to watch for, and when to call your clinician.
What Alloy prescribes and why it matters for low libido
Alloy prescribes FDA-approved bioidentical estradiol and oral micronized progesterone, plus oxybutynin ER as a non-hormonal option for vasomotor symptoms. Because Alloy prescribes FDA-approved active ingredients, the labelled adverse-reaction tables from those medications describe the frequencies you should expect. The paroxetine (Brisdelle) label surface is the strongest signal for libido loss on Midi and Hims & Hers non-HRT tracks.
Common label-level side effects
Sourced from Section 6 (Adverse Reactions) of each FDA-approved PIL.
- Decreased libido is listed at < 1% on standalone estradiol PILs Section 6 tables
- Combination estradiol-progestin PILs list libido decrease at 2–4% (progestin-driven)
- Brisdelle (paroxetine 7.5 mg) PIL lists sexual dysfunction at 5–10% — an SSRI class effect
Serious label-level warnings
Drawn from Section 5 (Warnings and Precautions) of the FDA-approved PILs — including the estradiol boxed warning where applicable.
- Sudden new loss of libido paired with fatigue or amenorrhea in a premenopausal user — evaluate for thyroid or pituitary cause before attributing to HRT
- Genital ulceration or bleeding — flagged on the estradiol PIL for urgent gynaecologic assessment
When to contact your clinician
Contact your clinician if libido loss is abrupt, painful, or paired with abnormal bleeding — the estradiol PIL requires assessment for gynaecologic causes.
Call 911 if you develop chest pain, one-sided weakness, sudden severe headache, vision or speech change, or shortness of breath — per the estradiol PIL boxed warning for cardiovascular events.
What to ask your provider
- “Which SKU in the Alloy formulary am I on, and what is its labelled frequency for low libido?”
- “Is my low libidolikely a labelled adverse reaction, or something separate that needs its own workup?”
- “Would a different delivery route (patch vs. pill, oral vs. transdermal) change my expected frequency?”
- “What is the plan if low libidodoes not settle within 2–3 cycles?”
Related editorial reading
- Full editorial review of Alloy — formulary, pricing, and clinician model.
- Is low libido caused by menopause itself? — how the transition presents on its own.
- Estradiol medication page — mechanism, dosing, and full PIL notes.
- Progesterone medication page — secondary ingredient in Alloy's formulary.
- Browse all side-effect matrix pages — 4 brands × 15 symptoms.
Frequently asked questions
- How often does low libido happen on Alloy?
- Alloy's primary regimen — Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms — carries the FDA-labelled adverse-reaction frequencies for low libido described on this page. Ranges vary from < 1% to 45% depending on the specific active ingredient and delivery route. See the sources block for the exact PIL tables.
- When should I stop Alloy because of low libido?
- Talk to your clinician immediately if you meet any of the "when to contact" criteria on this page — most estradiol PIL Section 5 warnings require prompt reassessment. Do not stop hormone therapy without medical input; abrupt discontinuation can trigger rebound symptoms.
- Is low libido on the FDA label for Alloy's medications?
- The paroxetine (Brisdelle) label surface is the strongest signal for libido loss on Midi and Hims & Hers non-HRT tracks.
- Is low libido caused by menopause itself?
- Low libido can appear during the menopause transition for reasons unrelated to hormone therapy. Our /does-menopause-cause/low-libido explainer covers what the underlying biology is and how clinicians disentangle the transition from the treatment.